¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"phase shift mutation"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
  • population mutation
    Áý´Üµ¹¿¬º¯ÀÌ
  • recessive mutation
    ¿­¼ºµ¹¿¬º¯ÀÌ
  • reverse mutation
    ¿ªµ¹¿¬º¯ÀÌ, º¹±Íµ¹¿¬º¯ÀÌ
  • somatic mutation
    ü¼¼Æ÷µ¹¿¬º¯ÀÌ
  • somatic mutation theory
    ü¼¼Æ÷µ¹¿¬º¯À̼³
  • spontaneous mutation
    ÀÚ¿¬µ¹¿¬º¯ÀÌ
  • suppressor mutation
    ¾ïÁ¦(µ¹¿¬)º¯ÀÌ
  • temperature-sensitive mutation
    ¿Âµµ¹Î°¨µ¹¿¬º¯ÀÌ
  • acceleration phase
    ÃËÁø±â, °¡¼Ó±â
  • active phase
    Ȱ¼º±â
  • acute phase reactant
    ±Þ¼º±â¹ÝÀÀ¹°Áú
  • acute phase reaction
    ±Þ¼º±â¹ÝÀÀ
  • acute phase serum
    ±Þ¼º±âÇ÷û
  • advanced sleep phase syndrome
    ÀüÁø¼ö¸éÀ§»óÁõÈıº
  • anal-sadistic phase
    Ç×¹®°¡Çбâ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
  • missense mutation
    °ú¿Àµ¹¿¬º¯ÀÌ
  • multiple allelic mutation
    ¹µ¸Â¼¶µ¹¿¬º¯ÀÌ
  • mutation rate
    µ¹¿¬º¯ÀÌÀ²
  • natural mutation
    ÀÚ¿¬µ¹¿¬º¯ÀÌ
  • nonsense mutation
    ¹«Àǹ̵¹¿¬º¯ÀÌ
  • plaque morphology mutation
    (¢¡plaque-type mutation) ÇöóÅ©Çüµ¹¿¬º¯ÀÌ
  • plaque-type mutation
    ÇöóÅ©Çüµ¹¿¬º¯ÀÌ
  • point mutation
    Á¡µ¹¿¬º¯ÀÌ
  • polar mutation
    ±Ø¼ºµ¹¿¬º¯ÀÌ
  • population mutation
    Áý´Ü±ºµ¹¿¬º¯ÀÌ
  • reading frame mutation
    ÇØµ¶Æ²µ¹¿¬º¯ÀÌ
  • recessive mutation
    ¿­¼ºµ¹¿¬º¯ÀÌ
  • reverse mutation
    ¿ªµ¹¿¬º¯ÀÌ, º¹±Íµ¹¿¬º¯ÀÌ
  • reversible mutation
    µÇÁý±âµ¹¿¬º¯ÀÌ, °¡¿ªµ¹¿¬º¯ÀÌ
  • somatic mutation
    ü¼¼Æ÷µ¹¿¬º¯ÀÌ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
  • implantational phase
    Âø»ó±â
  • in-phase image
    À§»ó³» ¿µ»ó
  • inactive phase
    ºñȰµ¿±â
  • inadequate luteal phase
    Ȳü±âºÎÀü(üÜô÷ÐïÝÕîï).
  • inadequate luteal phase
    Ȳü±âºÎÀü(üÜô÷ÐïÝÕîï).
  • inspiratory phase
    Èí±â»ó(ýåѨßÓ).
  • inspiratory phase time
    Èí±â»ó½Ã°£.
  • phallic stage (phase)
    ³²±Ù±â(ÑûÐÆÑ¢).
  • phase
    »ó, ±â
  • phase
    ˤȗ
  • phase 1 study
    ÀÓ»óÁ¦1»ó½ÃÇè.
  • phase I block
    Á¦1»óÂ÷´Ü.
  • phase advance
    »óÀüÁø(ßÓîñòä)
  • phase angle
    À§»ó°¢(êÈßÓÊÇ).
  • phase angle
    À§»ó °¢
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
  • cold-sensitive mutation
    ÇÑ·©°¨¼ö¼º µ¹¿¬º¯ÀÌ
  • complementation of virus mutation
    ¹ÙÀÌ·¯½ºº¯ÀÌ (Áõ½Ä)º¸¿Ï(¡­ñòãÖÜÍèÇ).
  • conditional lethal mutation
    Á¶°ÇÄ¡»ç µ¹¿¬º¯ÀÌ
  • conditional mutation
    Á¶°Çµ¹¿¬º¯ÀÌ
  • dominant mutation
    ¿ì¼º[µ¹¿¬]º¯ÀÌ
  • dominant mutation
    ¿ì¼º(µ¹¿¬)º¯ÀÌ(¡­ÔÍæ×ܨì¶).
  • drift mutation
    ¿¬¼Óº¯ÀÌ(ææáÙܨì¶).
  • frameshift mutation
    ÇØµ¶Æ² µ¹¿¬º¯ÀÌ, ÇÁ·¹ÀÓ½¬ÇÁÆ® µ¹¿¬º¯ÀÌ
  • frequency, mutation
    µ¹¿¬º¯À̺óµµ
  • gene mutation
    ÇØºÎ
  • gene mutation
    À¯ÀüÀÚµ¹¿¬º¯ÀÌ(ÔÍæÔܨì¶).
  • gene mutation
    À¯ÀüÀÚµ¹¿¬º¯ÀÌ.
  • gene mutation
    À¯ÀüÀÚµ¹¿¬º¯ÀÌ.
  • gene mutation
    À¯ÀüÀÚ(µ¹¿¬)º¯ÀÌ
  • genetic mutation
    À¯ÀüÀû µ¹¿¬º¯ÀÌ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
  • regeneration phase
    Àç»ý±â(î¢ßæÑ¢)
  • reversed phase chromatography
    ¿ª»ó(æ½ßÓ) Å©·Î¸¶Åä±×·¡ÇÇ
  • solid phase synthesis
    °í»óÇÕ¼º(ͳßÒùêà÷)
  • stationary phase
    "Á¤Áö»ó(ïÎò­ßÓ), Á¤Áö±â(ïÎò­Ñ¢)"
  • transient phase
    °úµµ»ó(ΦԤßÒ)
  • vapor phase chromatography
    Áõ±â»ó(ñúѨßÓ) Å©·Î¸¶Åä±×·¡ÇÇ
  • anucleolate mutation
    ¹«ÇÙÀÎ º¯ÀÌ(Ùíú·ìÝܨì¶)
  • back mutation
    º¹±Íº¯ÀÌ(ÜÖÏýܨì¶)
  • chain termination mutation
    »ç½½Çü¼º(û¡à÷) Á¾·á(ðûÖõ) º¯ÀÌ(ܨì¶)
  • constitutive mutation
    ±¸¼ºº¯ÀÌ(ϰà÷ܨì¶)
  • copy-error mutation
    º¹»ç¿À·ù º¯ÀÌ(ÜÜÞÐè¦×½Ü¨ì¶)
  • down promoter mutation
    ÇÏÇâÃËÁøÀÚ º¯ÀÌ(ù»ú¾õµòäí­Ü¨ì¶) (ÔÒ) promoter down mutation
  • end-point mutation
    Á¾¸»Á¡ º¯ÀÌ (ðûØÇïÇܨì¶)
  • forward mutation
    ³ªÅ¸³² º¯ÀÌ(ܨì¶)
  • frameshift mutation
    ƲÀ̵¿(ì¹ÔÑ) º¯ÀÌ(ܨì¶)
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 13 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
  • phase mismapping
    À§»ó¿ÀÁöµµÀÛ¼º
  • phase offset multiplannar [=POMP] imaging
    À§»ó¿ÀÇÁ¼Â´Ù¸é¿µ»ó
  • phase sensitive technique description
    À§»ó¹Î°¨¹ý¼³¸í
  • phase wrap
    À§»óÆ÷Àå
  • phase wraparound
    À§»óÆ÷Àå
  • phase wraparound artifact
    À§»óÆ÷ÀåÀΰø¹°
  • portal phase
    ¹®¸Æ±â
  • respiratory ordered phase encoding
    È£Èí¼øÀ§»óºÎȣȭ
  • resting phase
    È޽ıâ
  • spin phase
    ½ºÇÉÀ§»ó
  • spin phase effect
    ½ºÇÉÀ§»óÈ¿°ú
  • test phase
    ½ÃÇè±â
  • venous phase
    Á¤¸Æ»ó, Á¤¸Æ±â
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 4
PDS pain-dysfunction syndrome; paroxysmal depolarizing shift; patient data system; Patient-Doctor Societ...
PSVER pattern shift visual evoked response
SDS same day surgery; school dental services; self-rating depression scale; sensory deprivation syndrome...
TTS tarsal tunnel syndrome; temporary threshold shift; through the scope; through the skin; tilt table s...
LPD Luteal Phase Defect
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 4
EMSA Electrophoretic gel mobility shift assay
EMS Electrophoretic mobility shift
EMSA Electrophoretic mobility shift analyses
PSVEP Pattern Shift Visual Evoked Potentials
TTS Temporary Threshold Shift
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • anal-sadistic phase
    Ç×¹®-°¡Çбâ, Ç×¹®-°¡ÇÐ ½Ã±â
  • arousal phase
    ÀáÀ» ±ú´Â ½Ã±â
  • arterial phase
    µ¿¸Æ ±â
  • bacterial phase
    ¼¼±Õ »ó
    ¼¼±ÕÀÌ ´«¿¡ º¸ÀÌ´Â ¾ç»ó.
  • closing phase
    Æó±¸ ´Ü°è
  • dispersed phase
    ºÐ»ê »ó
  • equilibrium phase diagram
    ÆòÇü »óŵµ
    ÇÕ±ÝÀÇ Á¶¼º°ú ¿Âµµ°¡ ¹Ù²î¾îÁ³À» ¶§ÀÇ ÆòÇü »óÅ¿¡¼­ÀÇ »óÀÇ º¯È­¸¦ º¸ÀÎ ±×¸².
  • expiratory phase
    È£±â
  • exponential phase of growth
    ´ë¼ö Áõ½Ä±â, °¡¼Ó ¼ºÀå±â
  • implant surgical phase
    ¸Å½Ä ¿Ü°úÀû ´Ü°è
    ¸Å½Ä ÀÇÄ¡¸¦ Á¦ÀÛÇϱâ À§ÇÏ¿© Á¦1´Ü°èÀû »óÅ·Î, °ñ¸·À» ¾Ç°ñ¿¡¼­ ºÐ¸®ÇÏ¿© °ñ¸·ÀÌ ³ëÃâµÈ »óÅÂÀε¥ ¿©±â¼­ ÀλóÀÌ Ã¤µæµÈ´Ù. Á¦ 2´Ü°è´Â ±× °ñ¸é¿¡ ±Ý¼Ó ¸Å½Ä¹°À» ³õ°í ´Ù½Ã ºÀÇÕÇÏ¿© ¸Å½Ä¹°ÀÇ Áö´ëÄ¡°¡ ¿ÜºÎ·Î ³ëÃâµÇµµ·Ï ÇÏ´Â ´Ü°è. ÀÌ»óÀÇ µÎ ´Ü°è¸¦ ÀÏÄ´´Ù.
  • isotonic contraction phase
    µî·Â ¼öÃà±â
  • lactiferous phase
    ¼öÀ¯±â
  • lag phase
    ½Ãµ¿±â
  • late luteal phase dysphoric disorder
    ¸»±â Ȳü±â ºÒÄè Àå¾Ö
  • latency phase
    Àẹ±â
    º´¼Ò°¡ ħÀÔÇØ¼­ Áï½Ã °¨¿°À» ÀÏÀ¸Å°´Â °ÍÀÌ ¾Æ´Ï°í ¼÷ÁÖ ³»¿¡ ±â»ýÇϸ鼭 ÀûÀÀÇØ¼­ °¨¿°ÀÇ Áõ»óÀ» ³ªÅ¸³»±â±îÁöÀÇ ½Ã°£.
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 4
substitution mutation A mutation caused by a nucleotide base being replaced by a different one.
(09 Oct 1997)
nonsense mutation <molecular biology> A mutation that causes a polypeptide chain to be ended prematurely.
(13 Nov 1997)
null mutation Change in a gene that leads to nothing, for example to no enzyme or to a nonfunctioning enzyme.
(12 Dec 1998)
suppressor mutation <molecular biology> Mutation that alleviates the effect of a primary mutation at a different locus.
May be through almost any mechanism that can give a primary mutation, but perhaps the most interesting class are the amber and ochre supressors, where the anticodon of the tRNA is altered so that it mis reads the termination codon and inserts an amino acid, preventing premature termination of the peptide chain.
(18 Nov 1997)
deletion mutation <molecular biology> A mutation in which one or more (sequential) nucleotides is lost by the genome. If the number lost is not divisible by 3 and is in a coding region, the result is a frameshift mutation.
(18 Nov 1997)
down promoter mutation <molecular biology> A mutation (a change in base pair sequence) in a promoter region, this results in lower gene expression (less transcription of the gene occurs).
(09 Oct 1997)
induced mutation A mutation caused by exposure to a mutagen.
(05 Mar 2000)
insertion mutation A mutation caused by the insertion of at least one extra nucleotide basein a DNA sequence.
(09 Oct 1997)
ochre mutation Mutation that changes any codon to the termination codon UAA.
(18 Nov 1997)
opal mutation <molecular biology> Mutation that changes any codon to the termination codon UGA.
(18 Nov 1997)
temperature sensitive mutation <genetics, molecular biology> A type of conditional mutation in organism, somatic cell or virus that makes it possible to study genes whose total inactivation would be lethal. Such ts mutations can also make possible studies of the effect of reversible switching by temperature changes) in expression of the mutated gene. The usual mechanism of temperature sensitivity is that the mutated gene codes for a protein with a temperature dependent conformational instability, so that it possesses normal activity at one temperature (the permissive temperature), but is inactive at a second (nonpermissive) temperature.
(18 Nov 1997)
transition mutation A point mutation involving substitution of one base-pair for another, i.e., replacement of one purine for another and of one pyrimidine for another pyrimidine without change in the purine-pyrimidine orientation.
(05 Mar 2000)
transversion mutation A point mutation involving base substitution in which the orientation of purine and pyrimidine is reversed, in contradistinction to transition mutation.
(05 Mar 2000)
umber mutation A mutation yielding the termination codon UGA, resulting in premature termination of a polypeptide chain.
Compare: suppressor mutation.
Synonym: opal mutation.
(05 Mar 2000)
unstable mutation <molecular biology> A mutation that has a high likelihood of reverting to its original form.
(13 Nov 1997)
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 4
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 4
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 4
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 4
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 4
ÅëÇÕ°Ë»ö ¿Ï·á